- Home
- SUPN vs FRME Comparison
SUPN vs FRME Comparison
Compare SUPN & FRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- FRME
- Stock Information
- Founded
- SUPN 2005
- FRME 1893
- Country
- SUPN United States
- FRME United States
- Employees
- SUPN N/A
- FRME N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- FRME Major Banks
- Sector
- SUPN Health Care
- FRME Finance
- Exchange
- SUPN Nasdaq
- FRME Nasdaq
- Market Cap
- SUPN 2.6B
- FRME 2.3B
- IPO Year
- SUPN 2012
- FRME N/A
- Fundamental
- Price
- SUPN $44.80
- FRME $39.85
- Analyst Decision
- SUPN Buy
- FRME Buy
- Analyst Count
- SUPN 2
- FRME 3
- Target Price
- SUPN $43.00
- FRME $46.67
- AVG Volume (30 Days)
- SUPN 654.2K
- FRME 192.4K
- Earning Date
- SUPN 11-03-2025
- FRME 10-23-2025
- Dividend Yield
- SUPN N/A
- FRME 3.60%
- EPS Growth
- SUPN 1411.53
- FRME 23.41
- EPS
- SUPN 1.14
- FRME 3.85
- Revenue
- SUPN $665,125,000.00
- FRME $638,723,000.00
- Revenue This Year
- SUPN $4.84
- FRME $14.28
- Revenue Next Year
- SUPN $17.69
- FRME $4.02
- P/E Ratio
- SUPN $38.93
- FRME $10.38
- Revenue Growth
- SUPN 5.55
- FRME 6.22
- 52 Week Low
- SUPN $29.16
- FRME $33.13
- 52 Week High
- SUPN $46.79
- FRME $46.13
- Technical
- Relative Strength Index (RSI)
- SUPN 58.16
- FRME 47.05
- Support Level
- SUPN $43.44
- FRME $38.92
- Resistance Level
- SUPN $46.72
- FRME $40.48
- Average True Range (ATR)
- SUPN 1.08
- FRME 0.81
- MACD
- SUPN -0.48
- FRME -0.23
- Stochastic Oscillator
- SUPN 40.60
- FRME 29.43
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.